Key result
A red light-activated Ru(II)-based H2S-releasing agent increased intracellular H2S and protected H9c2 cardiomyoblasts from an in vitro model of ischemia-reperfusion injury.
A novel red light-activated ruthenium(II) complex effectively delivers intracellular hydrogen sulfide and protects cardiomyoblasts from ischemia-reperfusion injury in vitro.
Answers are grounded in this paper and cite their sources.
Red-light-activated Ru(II) H2S donor feasible in vitro; leaves open any role in ischemia-reperfusion injury pending in vivo studies.
Hydrogen sulfide (H 2 S) is a biological gasotransmitter that has been employed for the treatment of ischemia-reperfusion injury. Despite its therapeutic value, the implementation of this gaseous molecule for this purpose has required H 2 S-releasing prodrugs for effective intracellular delivery. The majority of these prodrugs, however, spontaneously release H 2 S via uncontrolled hydrolysis. Here, we describe a Ru(II)-based H 2 S-releasing agent that can be activated selectively by red light irradiation. This compound operates in living cells, increasing intracellular H 2 S concentration only upon irradiation with red light. Furthermore, the red light irradiation of this compound protects H9c2 cardiomyoblasts from an in vitro model of ischemia-reperfusion injury. These results validate the use of red light-activated H 2 S-releasing agents as valuable tools for studying the biology and therapeutic utility of this gasotransmitter.
No takes yet. Share an insight, caveat, or question.
Woods et al. (2018) studied Ischemia-reperfusion injury. Ru(II)-based H2S-releasing agent activated by red light was evaluated on Protection from in vitro model of ischemia-reperfusion injury. A red light-activated Ru(II)-based H2S-releasing agent increased intracellular H2S and protected H9c2 cardiomyoblasts from an in vitro model of ischemia-reperfusion injury.
Synapse has enriched 10 related papers. Consider them for comparative context: